A new study published in Nature Medicine describes results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person’s own immune system to recognize and destroy cancer cells. The results demonstrated a clinical response in 80 percent of advanced multiple myeloma patients after undergoing autologous stem cell transplants (ASCT). This time, researchers modified T cells to attack cancer cells expressing NY-ESO-1, an antigen found in nearly 60 percent of multiple myelomas and previously shown to be associated with tumor growth and poor prognosis. Department co-authors of the advance online publication include Drs. Carl June, Don Siegel, and Bruce Levine.
Read the Department of Communications news release.